Navigation Links
Medarex to Receive Milestone Payment from MedImmune for Allowance of an Investigational New Drug Application for MEDI-546
Date:2/2/2009

PRINCETON, N.J., Feb. 2 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) today announced that it will receive a milestone payment of $1 million from its partner, MedImmune, LLC for the allowance of an Investigational New Drug (IND) application for MEDI-546, a fully human antibody that targets a component of the type 1 interferon pathway. MEDI-546 will be studied in patients with scleroderma, a chronic autoimmune disease characterized by hardening and thickening of the skin and other organs.

"This IND application marks the second antibody targeting the interferon inflammatory pathway that MedImmune has supported for advancement into the clinic using our UltiMAb(R) technology," said Howard H. Pien, Chairman and CEO of Medarex.

In November 2004, MedImmune entered into collaboration with Medarex to focus on two specific antibodies, MDX-1103 (now known as MEDI-545) and MDX-1333 (now known as MEDI-546). Under the terms of the agreement, MedImmune is responsible for all ongoing clinical development activities. Prior to the beginning of pivotal studies, Medarex may elect to co-develop the products in return for the opportunity to co-promote and to receive a share of the commercial profits in the United States. In all other cases, Medarex will be entitled to receive milestone payments and royalties.

About Medarex

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates f
'/>"/>

SOURCE Medarex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Medarex Reviews Recent Highlights and Outlook for 2009
2. Medarex to Receive Milestone Payment for Approval of STELARA(TM) (Ustekinumab) for the Treatment of Moderate to Severe Plaque Psoriasis
3. Medarex Hosts June 2nd Webcast of Ipilimumab Data Presented at ASCO
4. Medarex Announces 2008 First Quarter Financial Results
5. Medarex and Bristol-Myers Squibb Joint Statement on Submission Status of Ipilimumab
6. Medarex Announces 2007 Fourth Quarter and Year End Financial Results
7. Medarex to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
8. Medarex to Receive Milestone Payment for Submission of Regulatory Applications Requesting Approval of Ustekinumab (CNTO 1275) for Treatment of Psoriasis
9. PharmAthene and Medarex Announce Additional $0.8 Million U.S. Government Appropriation for Continued Development of Anthrax Therapeutic Valortim(TM)
10. Medarex to Present at the JPMorgan Small/Mid Cap Conference
11. Ono and Medarex Announce Allowance of Investigational New Drug Application for Fully Human Anti-PD1 Antibody
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2014)... According to a new market research report ... (processor, GPU, DSP, connectivity), Technology Node (45nm-5nm), Application ... Forecast and Analysis to 2014-2020", published by MarketsandMarkets, ... is expected to reach $61.70 Billion by 2020, ... to 2020. , Browse 71 market data Tables ...
(Date:7/13/2014)... 13, 2014 A Massachusetts couple who ... cancer risks associated with power morcellators ( http://www.gynecaremorcellatorlawsuit.com/ ) ... to federal regulators, as they presented poignant testimony on ... Drug Administration (FDA) advisory panel meeting convened to address ... the Rochester Democrat and Chronicle, Dr. Hooman Noorchashm and ...
(Date:7/13/2014)... 2014 The Pearland, Texas location of The ... from four months to 12 years of age that offers ... birthday parties and Summer Camps, is now under new ownership. ... Pearland after spending over six years at The Little ... Director. , Berry has over ten years of experience ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 The federal ... ) filed against Johnson & Johnson’s Ethicon, ... trial, which is expected to get underway next month. ... the U.S. District Court, Southern District of West Virginia ... held on August 7, 2014 at 3:00 p.m. July ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 Max ... Famer, Chris Mullin, will be the featured guest at ... 26th in Puerto Rico. Attendees will learn about ... participate in two exhibition basketball games and perform in ... supplier of health- and energy-boosting supplements , has ...
Breaking Medicine News(10 mins):Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 4Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 2Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 3Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 4Health News:The Little Gym of Pearland, TX Now Under New Ownership and Management 2Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 2Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 3Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 4Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 2Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 3Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 4
... , , , ... http://www.avacor.com ) has acquired the assets ... name; Avacor,s FDA approved Physicians, Topical Formulation(R); the All-Natural Nutricap and ... Application) which allows the company to market and sell the FDA ...
... Going out like a brilliant flame is one way ... a form of programmed suicide called apoptosis, a desired effect ... could more quickly pick the most effective treatment. Now scientists ... way to do just that, by lighting up cells as ...
... A new study by researchers from the Automotive Safety Program ... Medicine published online July 13, 2009 in the journal ... health care needs are doing a good job with the ... help in using it correctly. The study, one of ...
... to aid in understanding childhood brain development and healthy ... Deficit Hyperactivity Disorder and detecting the early onset of ... million in recent funding from the Canadian Institutes of ... makes us human is the ability to control our ...
... , , WASHINGTON, July 13 ... creation of a National Diabetes Coordinator to develop and implement a nationwide ... , , A study commissioned by NCDP ... The coordinator would be responsible for establishing priorities in the fight ...
... , , , WASHINGTON, ... in Congress, the Institute for America,s Future today released the names ... All the experts favor a public health insurance option to compete with ... to the health care debate. , , ...
Cached Medicine News:Health News:Avacor(R), Premier Provider of Hair Growth Solutions, Acquired By Investor Group. 2Health News:Fluorescent probes may permit monitoring of chemotherapy effectiveness, Stanford study shows 2Health News:Fluorescent probes may permit monitoring of chemotherapy effectiveness, Stanford study shows 3Health News: Making the difficult task of transporting a child with special needs safer 2Health News:Queen's University study aims at early diagnosis for ADHD and Parkinson's disease 2Health News:Diabetes Advocates Call For National Strategy, Leadership to Reduce Diabetes and Advance Detection and Treatment 2Health News:Diabetes Advocates Call For National Strategy, Leadership to Reduce Diabetes and Advance Detection and Treatment 3Health News:Diabetes Advocates Call For National Strategy, Leadership to Reduce Diabetes and Advance Detection and Treatment 4Health News:Prominent Health Experts Who Support Public Insurance Option Available for Interview 2Health News:Prominent Health Experts Who Support Public Insurance Option Available for Interview 3Health News:Prominent Health Experts Who Support Public Insurance Option Available for Interview 4Health News:Prominent Health Experts Who Support Public Insurance Option Available for Interview 5
(Date:7/11/2014)... /PRNewswire-iReach/ -- VAPETEK™, Inc. has announced a new ... in portable vaporizers, which contains CBD, or cannabodiol. ... cannabidiol offers consumers a THC-free product made for ... technology. Photo - http://photos.prnewswire.com/prnh/20140711/126344 ... compounds which are currently known, two of which ...
(Date:7/11/2014)... July 11, 2014 The consumer marketing ... across industry sectors to better identify winning tools ... to engage with and understand consumers, as new ... make critical purchasing decisions. According ... LLC, one area where organizations can observe a ...
(Date:7/11/2014)... 11, 2014 Research and Markets ... Chinese Medical X-ray Film Industry Report 2014" report ... Global And Chinese Medical X-Ray Film ... on the current state of the Global medical X-ray ... The report provides a basic overview of the ...
Breaking Medicine Technology:VAPETEK Releases CBD-Infused eLiquid For The Consumer Market 2New Technologies Transforming Consumer Marketing Research Playbook 2Global and Chinese Medical X-ray Film Industry Report 2014 2
... WELLESLEY, Mass., Oct. 26 Coley,Pharmaceutical Group, Inc. ... company,has received a $3.0 million milestone payment from ... III clinical trial in,non-small cell lung cancer (NSCLC) ... adjuvant. In June 2007, GSK announced the ...
... at AACR-NCI-EORTC ... Symposium, ... MTAX: CTIC) and Systems Medicine, LLC (SM), a,wholly-owned subsidiary of CTI, ... 19th annual AACR-NCI-EORTC Symposium. "These studies show potential progress toward ...
Cached Medicine Technology:Coley Pharmaceutical Group Receives $3.0 Million Milestone Payment from GlaxoSmithKline 2Coley Pharmaceutical Group Receives $3.0 Million Milestone Payment from GlaxoSmithKline 3Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti-Cancer Compounds Early in Clinical Development 2Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti-Cancer Compounds Early in Clinical Development 3Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti-Cancer Compounds Early in Clinical Development 4Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti-Cancer Compounds Early in Clinical Development 5
Inquire...
Integrated closure system provides security you can feel as the plastic fasteners lock into place and is both easy to close, empty and clean....
Flextend is a hydrocolloid skin barrier that is designed to be the most resistant to discharge and is the barrier of choice for urostomies and high output ileosotomies....
Inquire...
Medicine Products: